Three independent discounted-cash-flow-style models value BioCryst Pharmaceuticals Inc every trading day. 0 of 3 currently price BCRX above its market price.
| Free Cash Flow model | $0.37 |
| Excess Profit model | $-37.56 |
| Residual Earnings model | $-0.22 |
| Dividend Discount model | — |
| Piotroski F-Score | 7 / 9 |
| Return on invested capital | +84.7% |
| Net debt / EBITDA | 1.0× |
| Gross margin | +97.8% |
| Revenue CAGR | +47.8% |
| Cash conversion | 1.3× |
| Dividend yield | — |
| Buyback yield | -1.5% |
These are StockKitty's default assumptions. In the app, the models recompute live as you adjust growth, discount rates, and margins — and the AI explains the bull case, bear case, and quality picture.
Open BCRX in StockKitty